- Details
- Zachary Klaassen hosts Sarah Howlett and Mahaz Kayani about the STAMPEDE2 platform trial, focusing on Arm N, which tests niraparib-abiraterone in metastatic hormone-sensitive prostate cancer patients with specific homologous recombination repair gene alterations. They discuss the trial's design, which randomizes patients to receive either a dual-action tablet of niraparib-abiraterone or standard A...
|
- Details
- Rashid Sayyid and Zach Klaassen discuss the ARANOTE trial, a phase III study evaluating darolutamide plus ADT in metastatic hormone-sensitive prostate cancer. They highlight the trial's design, which randomized 669 patients to darolutamide plus ADT or placebo plus ADT. The study meets its primary endpoint, showing significant improvement in radiographic progression-free survival for the darolutami...
|
- Details
- While most patients with prostate cancer are diagnosed with localized disease, a subset will develop metastatic disease, and subsequently castration-resistant prostate cancer (mCRPC), which remains incurable. Additionally, an increasing number of patients will present with de novo metastatic prostate cancer, known as metastatic castration-sensitive prostate cancer (mCSPC), and may progress to mCRP...
|
- Details
- Fred Saad and Neal Shore discuss the ARANOTE trial with Zach Klaassen, exploring the use of darolutamide plus ADT in metastatic hormone-sensitive prostate cancer. They highlight the trial's diverse patient population and impressive results, including a 46% reduction in radiographic progression-free survival risk. The conversation covers the efficacy of this doublet therapy in various subgroups, pa...
|
- Details
- Nicholas James and Gerhardt Attard discuss findings from the STAMPEDE trial, focusing on molecular profiling of prostate cancer tumors. They explore the use of the Decipher® genomic classifier as a prognostic and predictive tool for treatment decisions in metastatic prostate cancer. The conversation covers the test's ability to identify patients who are likely to benefit from abiraterone and, more...
|
- Details
- Nicholas James and Minal Padden-Modi discuss the STAMPEDE2 trial Arm P, which examines the use of upfront accelerated lutetium-PSMA-617 in metastatic hormone-sensitive prostate cancer. Dr. Padden-Modi outlines the trial design, which randomizes patients to standard of care with or without lutetium-PSMA-617, administered in an accelerated schedule. The trial includes an imaging sub-study to evaluat...
|
- Details
- Neeraj Agarwal interviews Fred Saad about the Phase III ARANOTE trial. The study investigates darolutamide plus ADT versus placebo plus ADT in metastatic hormone-sensitive prostate cancer. Dr. Saad discusses the trial's design, patient demographics, and key findings. The results show significant improvements in radiographic progression-free survival, time to mCRPC, pain progression, and PSA respon...
|
- Details
- Leslie Ballas interviews Hoda Abdel-Aty about the STAMPEDE2 SABR trial, a Phase III randomized study investigating stereotactic ablative body radiotherapy in newly diagnosed oligometastatic prostate cancer patients starting androgen deprivation therapy. Dr. Abdel-Aty discusses the trial design, which compares standard-of-care treatment with or without SABR to metastases. The study defines oligomet...
|
- Details
- Neeraj Agarwal interviews Arun Azad about the UpFrontPSMA study. Dr. Azad discusses the randomized Phase II trial comparing sequential lutetium-PSMA-617 and docetaxel versus docetaxel alone in metastatic hormone-sensitive prostate cancer (mHSPC). The study demonstrates significant improvements in the primary endpoint of undetectable PSA at 48 weeks and several secondary endpoints with the addition...
|
- Details
- Neeraj Agarwal interviews Marta Garcia de Herreros about presentation on tumor suppressor gene (TSG) signatures in metastatic hormone-sensitive prostate cancer (mHSPC). Dr. Garcia de Herreros discusses the TSG-low signature, based on low expression of RB1, PTEN, and TP53 genes, which predicts early progression to castration-resistant prostate cancer (CRPC) and the development of aggressive variant...
|
